The ability of various infections to suppress neoplastic growth is well-documented. We have previously demonstrated that tumor suppression during acute toxoplasmosis does not involve cytotoxic functions of the immune system and readily occurs in immunocompromised mice. Instead, it relies on systemic inhibition of angiogenesis by circulating factors, most likely interferons. To determine whether AIDS-related Burkitt lymphoma would succumb to infection-mediated suppression, we have established a new mouse model for this disease. It is based on overexpression of the c-Myc oncoprotein in p53-null bone marrow progenitors. Using this model, we have found that growth of B-lymphomas during acute toxoplasmosis was completely abolished. In this proposal, we will study mechanisms whereby type I and II interferons suppress lymphomagenesis. We will use STATI-null mice in which both type I and type II interferon pathways are inactivated, and determine whether in these animals angiogenesis during infection is restored. We will also determine whether growth of neoplastic B-cells is directly inhibited by interferons. To this end, we will cross STATI- and p53-null mice and generate B-lymphomas that are deficient in STATI expression. They will be implanted into Toxoplasma gondii-infected STATl -null mice. Since in this system both host and tumor cells are refractory to interferons, we expect that B-lymphomagenesis would be completely restored. This would suggest that interferons play a dual role in lymphoma surveillance during infection: direct and aniogenesis-mediated. We will then determine whether exposure to T.gondii antigens (STAg) would lead to the induction of interferons and suppression of angiogenesis and lymphomagenesis. We will also perform tumor load studies in STAg-treated scid-beige mice, to demonstrate that anti-neoplastic properties of STAg do not rely on cell-mediated cytotoxic immunity. This anticipated result will establish that STAg or similar protozoan or bacterial antigens could be developed into new therapeutic modalities for AIDS-related Burkitt lymphoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA097932-01
Application #
6553976
Study Section
Special Emphasis Panel (ZRG1-AARR-1 (09))
Program Officer
Yovandich, Jason L
Project Start
2002-07-01
Project End
2004-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
1
Fiscal Year
2002
Total Cost
$237,750
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Veterinary Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Yu, Duonan; Carroll, Martin; Thomas-Tikhonenko, Andrei (2007) p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood 109:4936-43
Cozma, Diana; Yu, Duonan; Hodawadekar, Suchita et al. (2007) B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. J Clin Invest 117:2602-10
Dews, Michael; Homayouni, Asal; Yu, Duonan et al. (2006) Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38:1060-5
Zhang, Xiao-Yong; DeSalle, Lauren M; Patel, Jagruti H et al. (2005) Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc Natl Acad Sci U S A 102:13968-73
Yu, Duonan; Dews, Michael; Park, Andrea et al. (2005) Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies. Cancer Res 65:5454-61
Yu, Duonan; Cozma, Diana; Park, Andrea et al. (2005) Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor. Ann N Y Acad Sci 1059:145-59
Rankin, Erinn B; Yu, Duonan; Jiang, Jiu et al. (2003) An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth. Cancer Biol Ther 2:687-93
Yu, Duonan; Allman, David; Goldschmidt, Michael H et al. (2003) Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood 101:1950-5
Thomas-Tikhonenko, Andrei; Hunter, Christopher A (2003) Infection and cancer: the common vein. Cytokine Growth Factor Rev 14:67-77
Burnham, D K; Mak, C K; Webster, R J et al. (1989) Relationship between inducible H-2 expression and the immunogenicity of murine skin neoplasms. I. Evidence that the immunogenicity of ultraviolet radiation-chemically induced tumors is associated with their susceptibility to gamma-interferon-mediated enha Transplantation 47:533-42